Meeting
2021 ASCO Annual Meeting
Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.
Authors
Cristina Gasparetto
Duke University Medical Center, Durham, NC
Cristina Gasparetto , Gary J. Schiller , Sascha Tuchman , Natalie Scott Callander , Muhamed Baljevic , Suzanne Lentzsch , Adriana C. Rossi , Rami Kotb , Darrell White , Nizar J. Bahlis , Christine Chen , Heather J. Sutherland , Sumit Madan , Richard LeBlanc , Michael Sebag , Christopher P. Venner , Noa Biran , Dane Van Domelen , Brea Lipe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 8038)
DOI
10.1200/JCO.2021.39.15_suppl.8038
Abstract #
8038
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM).
First Author: Cristina Gasparetto
Poster
2019 ASCO Annual Meeting
Overall survival (OS) with oral selinexor plus low dose dexamethasone (Sd) in patients with triple class refractory-multiple myeloma (TCR-MM).
First Author: Paul G. Richardson
Poster
2018 ASCO Annual Meeting
A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
First Author: Andrew Jenho Yee
Poster
2022 ASCO Annual Meeting
A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.
First Author: Andrew J Yee